Results 31 to 40 of about 3,373 (135)

A Serum N‐Glycan Ratio Associated With Disease Severity and Treatment Response in Psoriasis

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is a chronic, immune‐mediated inflammatory disease with heterogeneous manifestations. Reliable biomarkers reflecting disease severity and treatment response remain limited. Glycans—carbohydrate structures attached to proteins and lipids—play key roles in biological processes, contributing to functional specificity.
Kentarou Nishimura, Noritaka Oyama, Takumi Hasegawa, Hiroshi Kasamatsu, Takenao Chino, Takahiro Tokunaga, Kiyoshi Higashi, Koichi Saito, Keita Yamada, Minoru Hasegawa   +9 more
wiley   +1 more source

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026)

Contact Dermatitis, EarlyView.
ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter, Olivier Aerts, Tove Agner, Richard Brans, Magnus Bruze, Alicia Cannavó, Marie‐Noёlle Crépy, Ana M. Giménez‐Arnau, Margarida Gonçalo, An Goossens, Swen M. John, Carola Lidén, Suzana Ljubojević Hadžavdić, Vera Mahler, Mihaly Matura, Esen Özkaya, Maria Pesonen, Nadia Raison‐Peyron, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Ian R. White, S. Mark Wilkinson, Jeanne Duus Johansen   +23 more
wiley   +1 more source

A case of generalized pustular psoriasis

Vestnik Dermatologii i Venerologii, 2017
The article presents a clinical case of generalized pustular psoriasis. Complex therapy features for this rare and severe type of psoriasis are described.
V. A. Oklopkov, O. V. Pravdina, A. A. Chermoschentsev, T. V. Repina, E. I. Poleshuk, V. G. Gudoshnik, R. V. Gorodilov   +6 more
doaj   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo, Stefanie Ziehfreund, Enya Müller, Hanna Wecker, Stefanie Eyerich, Tilo Biedermann, Alexander Zink   +6 more
wiley   +1 more source

Treatment of generalized pustular psoriasis with Spesolimab: a case report and literature review

Pifu-xingbing zhenliaoxue zazhi
Objective To evaluate the efficacy and safety of Spesolimab in the treatment of generalized pustular psoriasis(GPP). Methods A 30 years old female with GPP was intravenously given 900 mg of Spesolimab once.
Xiaoqian LIANG, Zexi MI, Yaohan XU, Yongfeng CHEN   +3 more
doaj   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Przegląd Dermatologiczny, 2017
Introduction . Psoriasis is a chronic inflammatory skin disease affecting approximately 2–3% of the general population. It is a condition with immunological and genetic background, coexisting with psoriatic arthritis in about 25% of cases. Biologic drugs
Joanna Narbutt, Magdalena Trelińska, Anna Woźniacka, Irmina Olejniczak-Staruch, Aleksandra Lesiak   +4 more
doaj   +1 more source

Pustular psoriasis: pathophysiology and current treatment perspectives

Psoriasis: Targets and Therapy, 2016
Katie E Benjegerdes,1 Kimberly Hyde,2 Dario Kivelevitch,3 Bobbak Mansouri1,4 1Texas A&M Health Science Center College of Medicine, Temple, 2Texas A&M Health Science Center College of Medicine, Round Rock, 3Division of Dermatology, Baylor ...
Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B   +3 more
doaj  

Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis

Pifu-xingbing zhenliaoxue zazhi
Objective To explore the clinical efficacy and safety of secukinumab in the treatment of childhood generalized pustular psoriasis (GPP) in order to provide a new therapeutic strategy for childhood generalized pustular psoriasis.
Min YU, Zhanghong YING
doaj   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source